Cialis
Product Images NDC 43353-857

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Cialis (NDC 43353-857). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 20mg (43353 857)

Cialis 20 mg tablets carton label showing 12 tablets. The label displays the active ingredient tadalafil and includes dosage strength. It lists the labeler as Aphena Pharma Solutions - Tennessee, LLC and includes product NDC 43353-0857. The carton indicates prescription-only use.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Chemical Structure (Cialis Uspi F001 Structure V1)

Chemical structure of the active ingredient in Cialis, showing the molecular arrangement of its components including fused rings and functional groups characteristic of this compound.*

FDA Label Image

Figure (Cialis Uspi F001 V2)

A pharmacokinetic graph showing plasma tadalafil concentration (µg/L) on the vertical axis over time (hours) on the horizontal axis. The chart compares three dosing regimens: a single 20-mg dose, a single 5-mg dose, and a once-daily 5-mg dose following five consecutive days of administration, with data points and error bars indicating variability.*

FDA Label Image

Figure (Cialis Uspi F002 V1)

Four line graphs showing the difference in blood pressure measurements (systolic and diastolic) over time in hours for standing and supine positions, comparing Tadalafil to placebo. The graphs display mean differences with error bars plotted at multiple time points up to 96 hours.*

FDA Label Image

Figure (Cialis Uspi F003 V1)

A dual line graph showing the effect of tadalafil 20 mg combined with doxazosin 8 mg versus placebo with doxazosin 8 mg on systolic blood pressure. The top graph plots standing systolic BP over 24 hours post-dose, and the bottom graph plots supine systolic BP over the same time. Data points for tadalafil and placebo treatments are displayed with solid and dotted lines, respectively.*

FDA Label Image

Figure (Cialis Uspi F004 V1)

A line graph showing the effect on systolic blood pressure (mmHg) over 12 hours after administration of tadalafil 20 mg or placebo, each combined with 8 mg doxazosin. The x-axis represents time after administration in hours, and the y-axis represents changes in systolic blood pressure. The graph includes four lines comparing morning and evening dosing times.*

FDA Label Image

Figure 5 (Cialis Uspi F005 V1)

A line graph showing change from baseline in IPSS total score over 12 weeks for Cialis 5 mg versus placebo. The x-axis represents duration of treatment in weeks (0, 4, 8, 12), and the y-axis shows change from baseline in IPSS total score. Cialis 5 mg demonstrates a greater decrease in IPSS score compared to placebo, with statistically significant differences noted at 12 weeks (p < 0.01).*

FDA Label Image

Figure 6 (Cialis Uspi F006 V1)

A line graph comparing the change from baseline in IPSS total score over 12 weeks between Cialis 5 mg and placebo. The x-axis represents duration of treatment in weeks (0, 1, 4, 8, 12), and the y-axis shows change from baseline in IPSS total score, with lower scores indicating greater improvement. Cialis 5 mg shows a greater decrease in IPSS score compared to placebo, with statistically significant differences at weeks 4 and 12 (p<0.01).*

FDA Label Image

Figure 7 (Cialis Uspi F007 V2)

A line graph comparing the least squares mean change from baseline over 26 weeks of therapy between Tadalafil/Finasteride and Placebo/Finasteride treatments. The graph shows time in weeks on the x-axis and change from baseline on the y-axis, with data points for weeks 0, 4, 12, and 26. Statistical significance markers indicate differences between treatments at various time points.*

FDA Label Image

Figure 8 (Cialis Uspi F008 V1)

A line graph comparing the change from baseline in IPSS Total Score over 12 weeks between Cialis 5 mg and placebo. The x-axis represents treatment duration in weeks, and the y-axis represents the score change. Two lines depict the trends, showing greater improvement with Cialis 5 mg versus placebo, with statistical significance indicated at week 12.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.